Diabetic foot ulcers (DFUs) have a complex pathophysiology and require an expert multidisciplinary treatment. There are several, both systemic and local, risk factors for DFUs. A recent meta-analysis of 18 studies has now provided robust evidence on the detrimental effect of smoking on healing of DFUs. Indeed, healing rates were consistently lower among smokers than among nonsmokers. Based on this new evidence, it is reasonable to consider the utility of smoking cessation programs. Incorporation of the latter into the holistic therapeutic strategy for DFUs may be anticipated to improve healing rates, but this remains to be shown.
BoultonAJVileikyteLRagnarson-TennvallGApelqvistJ. The global burden of diabetic foot disease. Lancet. 2005;366:1719-1724.
2.
YotsuRRPhamNMOeMet al. Comparison of characteristics and healing course of diabetic foot ulcers by etiological classification: neuropathic, ischemic, and neuro-ischemic type. J Diabetes Complications. 2014;28:528-535.
3.
CrawfordFInksterMKleijnenJFaheyT. Predicting foot ulcers in patients with diabetes: a systematic review and meta-analysis. QJM. 2007;100:65-86.
4.
Monteiro-SoaresMBoykoEJRibeiroJRibeiroIDinis-RibeiroM. Predictive factors for diabetic foot ulceration: a systematic review. Diabetes Metab Res Rev. 2012;28:574-600.
5.
ZhangPLuJJingYTangSZhuDBiY. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis†. Ann Med. 2017;49:106-116.
6.
ZhouZYLiuYKChenHLYangHLLiuF. HbA1c and lower extremity amputation risk in patients with diabetes: a meta-analysis. Int J Low Extrem Wounds. 2015;14:168-177.
7.
ShinJYRohSGLeeNHYangKM. Influence of epidemiologic and patient behavior-related predictors on amputation rates in diabetic patients: systematic review and meta-analysis. Int J Low Extrem Wounds. 2017;16:14-22.
8.
KimJLShinJYRohSGChangSCLeeNH. Predictive laboratory findings of lower extremity amputation in diabetic patients: meta-analysis. Int J Low Extrem Wounds. 2017;16:260-268.
9.
VasPRJEdmondsMKavarthapuVet al. The diabetic foot attack: “tis too late to retreat!”Int J Low Extrem Wounds. 2018;17:7-13.
10.
BakheitHEMohamedMFMahadiSEet al. Diabetic heel ulcer in the Sudan: determinants of outcome. J Foot Ankle Surg. 2012;51:152-155.
11.
DhatariyaKKWah-Pun SinELPChengJOSet al. The impact of glycaemic variability on wound healing in the diabetic foot—a retrospective study of new ulcers presenting to a specialist multidisciplinary foot clinic. Diabetes Res Clin Pract. 2018;135:23-29.
12.
MusaHGAhmedME. Associated risk factors and management of chronic diabetic foot ulcers exceeding 6 months’ duration. Diabet Foot Ankle. 2012;3. doi:10.3402/dfa.v3i0.18980
13.
GershaterMALondahlMNybergPet al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia. 2009;52:398-407.
14.
LiuMZhangWYanZYuanX. Smoking increases the risk of diabetic foot amputation: a meta-analysis. Exp Ther Med. 2018;15:1680-1685.
15.
FuXLDingHMiaoWWChenHL. Association between cigarette smoking and diabetic foot healing: a systematic review and meta-analysis. Int J Lower Extrem Wounds. 2018;17:247-257.
16.
HolscherCMHicksCWCannerJKet al. Unplanned 30-day readmission in patients with diabetic foot wounds treated in a multidisciplinary setting. J Vasc Surg. 2018;67:876-886.
17.
LefrancoisTMehtaKSullivanVLinSGlazebrookM. Evidence based review of literature on detriments to healing of diabetic foot ulcers. Foot Ankle Surg. 2017;23:215-224.
18.
PapanasNMaltezosE. Glycated hemoglobin as a risk factor for lower extremity amputations in diabetes: “success is counted sweetest.”Int J Low Extrem Wounds. 2015;14:106-107.
19.
PapanasNManiR. How to cope with the increasing burden of the diabetic foot: “better three hours too soon than a minute too late.”Int J Low Extrem Wounds. 2014;13:171-172.
20.
DemetriouMPapanasNPanopoulouMPapatheodorouKBounovasAMaltezosE. Tissue and swab culture in diabetic foot infections: neuropathic versus neuroischemic ulcers. Int J Low Extrem Wounds. 2013;12:87-93.
21.
McDanielJCBrowningKK. Smoking, chronic wound healing, and implications for evidence-based practice. J Wound Ostomy Continence Nurs. 2014;41:415-423.
22.
JorenbyDEHaysJTRigottiNAet al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
23.
OnckenCGonzalesDNidesMet al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577.
24.
EbbertJOWyattKDHaysJTKleeEWHurtRD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence. 2010;4:355-362.
25.
ThunMJCarterBDFeskanichDet al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368:351-364.
